Efficacy, safety, and tolerability of ulotaront (SEP-363856, a trace amine-associated receptor 1 agonist) for the treatment of schizophrenia and other mental disorders: a systematic review of preclinical and clinical trials

References

• James SL, Abate D, Abate KH, et al. 2018. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990–2017: a systematic analysis for the global burden of disease study 2017. Lancet. 392(10159): 1789–1858. DOI:10.1016/S0140-67361832279-7
   PubMed Web of Science ®Google Scholar
• World Health Organization - Schizophrenia [Internet]. WHO; 2022 [cited 2022 Jul 15]. Available from: https://www.who.int/news-room/fact-sheets/detail/schizophrenia
   Google Scholar
• Chien WT, Leung SF, Yeung FKK, et al. Current approaches to treatments with schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care. Neuropsychiatr Dis Treat. 2013;9:1463–1481.
   PubMed Web of Science ®Google Scholar
• Talaslahti T, Alanen HM, Hakko H, et al. Mortality and causes of death in older patients with schizophrenia. Int J Geriatr Psychiatry. 2012;27(11):1131–1137.
   PubMed Web of Science ®Google Scholar
• Rhee TG, Rosenheck RA. Does improvement in symptoms and quality of life in chronic schizophrenia reduce family caregiver burden. Psychiatry Res. 2019;271:402–404.
   PubMed Web of Science ®Google Scholar
• Chong HY, Teoh SL, DBC W, et al. Global economic burden of schizophrenia: a systematic review. Neuropsychiatr Dis Treat. 2016;12:357–373.
   PubMed Web of Science ®Google Scholar
• Hjorthøj C, Stürup AE, McGrath JJ, et al. Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet. 2017;4(4):295–301.
   PubMed Web of Science ®Google Scholar
• Hoertel N, Rotenberg L, Blanco C, et al. Psychiatric symptoms and quality of life in older adults with schizophrenia spectrum disorder: results from a multicenter study. Eur Arch Psychiatry Clin Neurosci. 2020;270(6):673–688
   PubMed Web of Science ®Google Scholar
• Laruelle M. Schizophrenia: from dopaminergic to glutamatergic interventions. Curr Opin Pharmacol. 2014;14:97–102.
   PubMed Web of Science ®Google Scholar
• Brisch R, Saniotis A, Wolf R, et al. The role of dopamine in schizophrenia from a neurobiological and evolutionary perspective: old fashioned, but still in vogue. Front Psychiatry. 2014;5:47.
   PubMed Web of Science ®Google Scholar
• Shen LH, Liao MH, Tseng YC. Recent advances in imaging of dopaminergic neurons for evaluation of neuropsychiatric disorders. J Biomed Biotechnol. 2012;2012:259349.
   PubMedGoogle Scholar
• Stępnicki P, Kondej M, Kaczor AA. Current concepts and treatments of schizophrenia. Molecules. 2018;23(8):2087.
   PubMed Web of Science ®Google Scholar
• Howes OD, McCutcheon R, Owen MJ, et al. The role of genes, stress and dopamine in the development of schizophrenia. Biol Psychiatry. 2017;81(1):9–20.
   PubMed Web of Science ®Google Scholar
• Singam AP, Mamarde A, Behere PB. A single blind comparative clinical study of the effects of chlorpromazine and risperidone on positive and negative symptoms in patients of schizophrenia. Indian J Psychol Med. 2011;33(2):134–140
   PubMedGoogle Scholar
• Uno Y, Coyle JT. Glutamate hypothesis in schizophrenia. Psychiatry Clin Neurosci. 2019;73(5):204–215.
   PubMed Web of Science ®Google Scholar
• Heffernan MLR, Herman LW, Brown S, et al. Ulotaront: a TAAR1 agonist for the treatment of schizophrenia. ACS Med Chem Lett. 2022;13(1):92–98.
   PubMed Web of Science ®Google Scholar
• Cha DS, McIntyre RS. Treatment-emergent adverse events associated with atypical antipsychotics. Expert Opin Pharmacother. 2012;13(11):1587–1598.
   PubMed Web of Science ®Google Scholar
• Kane J, Honigfeld G, Singer J, et al. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45(9):789–796.
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373(9657):31–41.
   PubMed Web of Science ®Google Scholar
• Ricci V, Paggi A, Cristofori E, et al. Efficacy of brexpiprazole for treatment persistent negative symptoms in three schizophrenic patients: a case series. Case Rep Psychiatry. 2022;1(2):100040.
   Google Scholar
• Viegas F, Ferreira T, Campos C. Using cariprazine to ameliorate negative symptoms and metabolic side effects of clozapine and paliperidone – clinical cases. Neuropsychiatr Dis Treat. 2022;18:1145–1149.
   PubMed Web of Science ®Google Scholar
• Liang L, Ren X, Xu J, et al. Effects of co-treatment of olanzapine with SEP-363856 in mice models of schizophrenia. Molecules. 2022;27(8):2550
   PubMed Web of Science ®Google Scholar
• Hert MD, Detraux J, van Winkel R, et al. Metabolic and cardiovascular adverse effects associated with antipsychotic drugs. Nat Rev Endocrinol. 2011;8(2):114–126.
   PubMed Web of Science ®Google Scholar
• Leucht S, Chaimani A, Leucht C, et al. 60 years of placebo-controlled antipsychotic drug trials in acute schizophrenia: meta-regression of predictors of placebo response. Schizophr Res. 2018;201:315–323.
   PubMed Web of Science ®Google Scholar
• Girgis RR, Zoghbi AW, Javitt DC, et al. The past and future of novel, non-dopamine-2 receptor therapeutics for schizophrenia: a critical and comprehensive review. J Psychiatr Res. 2019;108:57–83.
   PubMed Web of Science ®Google Scholar
• Bender AM, Jones CK, Lindsley CW. Classics in Chemical Neuroscience: xanomeline. ACS Chem Neurosci. 2017;8(3):435–443.
   PubMed Web of Science ®Google Scholar
• Brannan SK, Sawchak S, Miller AC, et al. Muscarinic cholinergic receptor agonist and peripheral antagonist for schizophrenia. N Engl J Med. 2021;384(8):717–726.
   PubMed Web of Science ®Google Scholar
• Alnefeesi Y, Tamura JK, Lui LMW, et al. Trace amine-associated receptor 1 (TAAR1): potential application in mood disorders: a systematic review. Neurosci Biobehav Rev. 2021;131:192–210.
   PubMed Web of Science ®Google Scholar
• Dedic N, Dworak H, Zeni C, et al. Therapeutic potential of TAAR1 agonists in schizophrenia: evidence from preclinical models and clinical studies. Int J Mol Sciences. 2021;22(24):13185. DOI:10.3390/ijms222413185
   PubMed Web of Science ®Google Scholar
• Leo D, Mus L, Espinoza S, et al. Taar1-mediated modulation of presynaptic dopaminergic neurotransmission: role of D2 dopamine autoreceptors. Neuropharmacology. 2014;81:283–291.
   PubMed Web of Science ®Google Scholar
• Bradaia A, Trube G, Stalder H, et al. The selective antagonist EPPTB reveals TAAR1-mediated regulatory mechanisms in dopaminergic neurons of the mesolimbic system. Proc Natl Acad Sci, USA. 2009;106(47):20081–20086.
   PubMed Web of Science ®Google Scholar
• Rutigliano G, Accorroni A, Zucchi R. The case for TAAR1 As a modulator of central nervous system function. Front Pharmacol. 2018;8:987.
   PubMed Web of Science ®Google Scholar
• Berry MD. Mammalian central nervous system trace amines. Pharmacological amphetamines, physiological neuromodulators. J Neurochem. 2004;90(2):257–271.
   PubMed Web of Science ®Google Scholar
• Revel FG, Moreau JL, Gainetdinov RR, et al. Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics. Biol Pscyhiatry. 2012;72(11):934–942. DOI:10.1016/j.biopsych.2012.05.014
   PubMed Web of Science ®Google Scholar
• Revel FG, Moreau JL, Pouzet B, et al. A new perspective for schizophrenia: tAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight. Mol Psychiatry. 2013;18(5):543–556.
   PubMed Web of Science ®Google Scholar
• Koblan KS, Kent J, Hopkins SC, et al. A non-D2-receptor-binding drug for the treatment of schizophrenia. N Engl J Med. 2020;382(16):1497–1506.
   PubMed Web of Science ®Google Scholar
• Correll CU, Koblan KS, Hopkins SC, et al. Safety and effectiveness of ulotaront (SEP-363856) in schizophrenia: results of a 6-month, open-label extension study. NPJ Schizophr. 2021;7(1):63.
   PubMed Web of Science ®Google Scholar
• Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG. Assessing risk of bias in included studies. In: Higgins JP Green S, editors. Cochrane handbook for systematic reviews of interventions. John Wiley and Sons; 2008. p. 187–241. DOI:10.1002/9780470712184.ch8.
   Google Scholar
• Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Haddaway NR, Page MJ, Pritchard CC, et al. PRISMA2020: an R package and shiny app for producing prisma 2020-compliant flow diagrams, with interactivity for optimised digital transparency and open synthesis. Campbell Systematic Reviews. 2020;18:e1230. DOI:10.1002/cl2.1230
   Google Scholar
• Hopkins SC, Dedic N, Koblan KS. Effect of TAAR1/5-HT1A agonist SEP-363856 on REM sleep in humans. Transl Psychiatry. 2021;11(1):228.
   PubMed Web of Science ®Google Scholar
• Galluppi GR, Polhamus DG, Fisher JM, et al. Population pharmacokinetic analysis of ulotaront in subjects with schizophrenia. CPT Pharmacometrics Syst Pharmacol. 2021;10(10):1245–1254.
   PubMedGoogle Scholar
• Hopkins SC, Ogirala A, Worden M, et al. Depicting safety profile of TAAR1 agonist ulotaront relative to reactions anticipated for a dopamine d2-based pharmacological class in FAERS. Clin Drug Investig. 2021;41(12):1067–1073.
   PubMed Web of Science ®Google Scholar
• Begni V, Sanson A, Luoni A, et al. Towards novel treatments for schizophrenia: molecular and behavioral signatures of the psychotropic agent SEP-363856. Int J Mol Sci. 2021;22(8):4119
   PubMed Web of Science ®Google Scholar
• Dedic N, Jones PG, Hopkins SC, et al. SEP-363856, a novel psychotropic agent with a unique, Non-D2 receptor mechanism of action. J Pharmacol Exp Ther. 2019;371(1):1–14.
   PubMed Web of Science ®Google Scholar
• Xiao G, Chen YL, Dedic N, et al. In Vitro ADME And preclinical pharmacokinetics of ulotaront, a TAAR1/5-HT1A receptor agonist for the treatment of schizophrenia. Pharm Res. 2022;39:837–850.
   PubMed Web of Science ®Google Scholar
• Kokkinou M, Irvine EE, Bonsall DR, et al. Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine. Mol Psychiatry. 2021;26(6):2562–2575.
   PubMed Web of Science ®Google Scholar
• Nahar L, Delacroix BM, Nam HW. The role of parvalbumin interneurons in neurotransmitter balance and neurological disease. Front Psychiatry. 2021;12:679960.
   PubMed Web of Science ®Google Scholar
• Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nat Rev Neurosci. 2016;17(8):524–532.
   PubMed Web of Science ®Google Scholar
• Hofstetter JR, Lysaker PH, Mayeda AR. Quality of sleep in patients with schizophrenia is associated with quality of life and coping. BMC Psyfchiatry. 2005;5:13.
   PubMed Web of Science ®Google Scholar
• Wang YQ, Li R, Zhang MQ, et al. The neurobiological mechanisms and treatments of REM sleep disturbances in depression. Curr Neuropharmacol. 2015;13(4):543–553.
   PubMed Web of Science ®Google Scholar
• Estrada-Prat X, Álvarez-Guerrico I, Batlle-Vila S, et al. Sleep alterations in pediatric bipolar disorder versus attention deficit disorder. Psychiatry Res. 2019;275:39–45.
   PubMed Web of Science ®Google Scholar
• Kurian SM, Le-Niculescu H, Patel SD, et al. Identification of blood biomarkers for psychosis using convergent functional genomics. Mol Psychiatry. 2011;16(1):37–58.
   PubMed Web of Science ®Google Scholar
• Cattane N, Minelli A, Milanesi E, et al. Altered gene expression in schizophrenia: findings from transcriptional signatures in fibroblasts and blood. PLoS ONE. 2015;10(2):20116686. DOI:10.1371/journal.pone.0116686
   Web of Science ®Google Scholar
• Gallo FT, Katche C, Morici JF, et al. Immediate early genes, memory and psychiatric disorders: focus on c-Fos, Egr1 and Arc. Front Behav Neurosci. 2018;12:79.
   PubMed Web of Science ®Google Scholar
• Czobor P, Sebe B, Acsai K, et al. What is the minimum clinically important change in negative symptoms of schizophrenia? PANSS based post-hoc analyses of a phase III clinical trial. Front Psychiatry. 2022;13:816339.
   PubMed Web of Science ®Google Scholar
• Espinoza S, Salahpour A, Masri B, et al. Functional interaction between trace amine-associated receptor 1 and dopamine D2 receptor. Mol Pharmacol. 2011;80(3):416–425.
   PubMed Web of Science ®Google Scholar
• Harmeier A, Obermueller S, Meyer CA, et al. Trace amine-associated receptor 1 activation silences GSK3β signaling of TAAR1 and D2R heteromers. Eur Neuropsychopharmacol. 2015;25(11):2049–2061.
   PubMed Web of Science ®Google Scholar
• Revel FG, Moreau J-L, Gainetdinov RR, et al. TAAR1 activation modulates monoaminergic neurotransmission, preventing hyperdopaminergic and hypoglutamatergic activity. Proc Natl Acad Sci, USA. 2011;108(20):8485–8490.
   PubMed Web of Science ®Google Scholar
• Beaulieu J-M, Gainetdinov RR, Caron MG. Akt/GSK3 signaling in the action of psychotropic drugs. Annu Rev Pharmacol Toxicol. 2009;49:327–347.
   PubMed Web of Science ®Google Scholar
• Urs NM, Snyder JC, Jacobsen JPR, et al. Deletion of GSK3β in D2R-expressing neurons reveals distinct roles for β-arrestin signaling in antipsychotic and lithium action. Proc Natl Acad Sci U S A. 2012;109(50):20732–20737.
   PubMed Web of Science ®Google Scholar
• Terzić T, Kastelic M, Dolžan V, et al. Influence of 5-HT1A and 5-HTTLPR genetic variants on the schizophrenia symptoms and occurrence of treatment-resistant schizophrenia. Neuropsychiatr Dis Treat. 2015;11:453–459.
   PubMed Web of Science ®Google Scholar
• Bantick RA, Deakin JF, Grasby PM. The 5-HT1A receptor in schizophrenia: a promising target for novel atypical neuroleptics? J Psychopharmacol. 2001;15(1):37–46.
   PubMed Web of Science ®Google Scholar
• Puig MV, Artigas F, Celada P. Modulation of the activity of pyramidal neurons in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA. Cereb Cortex. 2005;15(1):1–14.
   PubMed Web of Science ®Google Scholar
• Euston DR, Gruber AJ, McNaughton BL. The role of medial prefrontal cortex in memory and decision making. Neuron. 2012;76(6):1057–1070.
   PubMed Web of Science ®Google Scholar
• Deng C. Effects of antipsychotic medications on appetite, weight, and insulin resistance. Endocrinol Metab Clin North Am. 2013;42(3):545–563.
   PubMed Web of Science ®Google Scholar
• Burghardt KJ, Seyoum B, Mallisho A, et al. Atypical antipsychotics, insulin resistance and weight; a meta-analysis of healthy volunteer studies. Prog Neuro Psychopharmacol Biol Psychiatry. 2018;83:55–63.
   PubMed Web of Science ®Google Scholar
• Dayabandara M, Hanwella R, Ratnatunga S, et al. Antipsychotic-associated weight gain: management strategies and impact on patient adherence. Neuropsychiatr Dis Treat. 2017;13:2231–2241.
   PubMed Web of Science ®Google Scholar
• Kotorki P, Pelka P, Leotsakou C, et al. Reversal of symptomatic antipsychotic-induced hyperprolactinemia with addition of aripiprazole. Ann Gen Psychiatry. 2010;9:S164.
   Google Scholar
• Latif Z, Jabbar F, Kelly BD. Clozapine and blood dyscrasia. The Psych. 2011;35(1):27–29.
   Google Scholar
• Sunovion. A clinical study to investigate the effect of an investigational drug as an added medication to an antipsychotic, in adults with schizophrenia, as measured Positron Emission Tomography (PET) imaging. ClinicalTrials.Gov identifier: nCT04038957. Updated Jul 11, 2022. Accessed Aug 13, 2022. https://clinicaltrials.gov/show/NCT04038957
   Google Scholar
• Sunovion. A clinical study to determine whether an investigational medication (sep-363856) changes how long it takes for food to move through the stomach into the small intestine in patients with schizophrenia. the study will help to understand any effect sep-363856 may have on blood sugar levels after a meal. ClinicalTrials.Gov identifier: nCT05402111. Updated Aug 2, 2022. Accessed Aug 13, 2022. https://clinicaltrials.gov/show/NCT05402111
   Google Scholar
• Sunovion. A clinical study that will look at an investigational medication, SEP-363856 (Called “Study Medication”) in patients with schizophrenia and assess whether it changes: how the body processes (uses) glucose (blood sugar), how much insulin the pancreas can make. ClinicalTrials.gov identifier: NCT05463770. Updated Jul 19, 2022. Accessed Aug 13, 2022. https://clinicaltrials.gov/show/NCT05463770
   Google Scholar
• Sumitomo Pharma Co., Ltd. A clinical trial to evaluate the efficacy and safety of SEP-363856 in acutely psychotic people with schizophrenia, followed by an open-label extension phase. ClinicalTrials.gov identifier: NCT04825860. Updated Apr 12, 2022. Accessed Aug 14, 2022. https://clinicaltrials.gov/show/NCT04825860
   Google Scholar
• Sunovion. A study to evaluate the efficacy, safety and tolerability of SEP-363856 in subjects with parkinson’s disease psychosis. ClinicalTrials.Gov identifier: nCT02969369. Updated Aug 4, 2021. Accessed Aug 14, 2022. https://clinicaltrials.gov/show/NCT02969369
   Google Scholar
• Sumitomo Pharma Co., Ltd. A clinical trial to evaluate the long-term safety and tolerability of SEP-363856 in patients with schizophrenia in Japan. ClinicalTrials.gov identifier: NCT05359081. Updated Jul 7, 2022. Accessed Aug 14, 2022. https://clinicaltrials.gov/show/NCT05359081
   Google Scholar
• Sunovion. A clinical study to evaluate the long-term safety and tolerability of an investigational drug in people with schizophrenia. ClinicalTrials.Gov identifier: nCT04109950. Updated Aug 2, 2022. Accessed Aug 14, 2022. https://clinicaltrials.gov/show/NCT04109950
   Google Scholar
• Sunovion. A clinical trial that will study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. ClinicalTrials.Gov identifier: nCT04092686. Updated Aug 2, 2022. Accessed Aug 15, 2022. https://clinicaltrials.gov/show/NCT04092686
   Google Scholar
• Sunovion. A clinical trial to study the efficacy and safety of an investigational drug in acutely psychotic people with schizophrenia. ClinicalTrials.Gov identifier: nCT04072354. Updated Aug 2, 2022. Accessed Aug 15, 2022. https://clinicaltrials.gov/show/NCT04072354
   Google Scholar
• Sunovion. A study of the long-term safety and tolerability of an investigational drug in people with schizophrenia. ClinicalTrials.gov identifier: NCT04115319. Updated Feb 17, 2022. Accessed Aug 15, 2022. https://clinicaltrials.gov/show/NCT04115319
   Google Scholar
• Zhang Y, Gruber R. Can slow-wave sleep enhancement improve memory? a review of current approaches and cognitive outcomes. Yale J Biol Med. 2019;92(1):63–80.
   PubMed Web of Science ®Google Scholar
• Cirillo MA, Seidman LJ. Verbal declarative memory dysfunction in schizophrenia: from clinical assessment to genetics and brain mechanisms. Neuropsychol rev. 2003;13(2):43–77.
   PubMed Web of Science ®Google Scholar
• Iorio C, Pacitti F, Rossi A, et al. Declarative memory impairment and emotional bias in recurrent depression with a seasonal pattern: the interplay between emotion and cognition in seasonal affective disorder. Brain Sci. 2022;12(10):1352.
   PubMed Web of Science ®Google Scholar